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Background: Coumarins are an important class of widely distributed heterocyclic natural products exhibiting a
broad pharmacological profile. In this work, a new series of coumarins bearing substituted 3,4-dihydro-2H-
benzothiazines were described as potential analgesic agents. The clinical use of NSAIDs as traditional analgesics is
associated with side effects such as gastrointestinal lesions and nephrotoxicity. Therefore, the discovery of new safer
drugs represents a challenging goal for such a research area.
Results: The target compounds 3-(3-methyl-3,4-dihydro-2H-benzo[b][1,4]thiazin-3-yl)-2H-chromen-2-ones 2a-u were
synthesized and characterized by spectral data. The antinociceptive properties of target compounds were
determined by formalin-induced test and acetic acid-induced writhing test in mice. Among the tested compounds,
compound 2u bearing 2-(4-(methylsulfonyl)benzoyl)- moiety on benzothiazine ring and 4-(methylsulfonyl)phenacy-
loxy- group on the 7 position of coumarin nucleus showed better profile of antinocecieption in both models. It
was more effective than mefenamic acid during the late phase of formalin-induced test as well as in the acetic
acid-induced writhing test.
Conclusion: Considering the significant antinoceciptive action of phenacyloxycoumarin derivatives, compound 2u
prototype might be further used as model to obtain new more potent analgesic drugs.
Keywords: Analgesic activity, Antinociception, Coumarin, Benzothiazine, Formalin test, Writhing testIntroduction
Pain is an uncomfortable sensation that alerts the hu-
man organs about a current or potential damage to tis-
sues [1]. It has been accepted that pain can widely
affect human life quality, and its management is con-
sidered as a main challenge in pharmacotherapy [2].
NSAIDs are one of major classes of traditional analge-
sics for treatment of pain. The clinical use of NSAIDs
is associated with side effects such as gastrointestinal
lesions and nephrotoxicity [3]. Therefore, the discovery
of new safer drugs represents a challenging goal for
such a research area.* Correspondence: ashafiee@ams.ac.ir
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reproduction in any medium, provided the orCoumarins are an important class of widely distributed
heterocyclic natural products exhibiting a broad pharmaco-
logical profile [4]. Several coumarin derivatives have been
synthesized with diverse biological activities [5-9] especially
analgesic/anti-inflammatory activity [10-13]. Recently, the
synthesis and anti-inflammatory/analgesic activities of sev-
eral coumarin derivatives with various substitutions on 3-
position of coumarin nucleus have been reported [14-16].
On the other hand, benzothiazine derivatives are also
important heterocyclic compounds with wide spectrum of
biological activities [17,18]. In view of the above facts and
in continuation of our research program on the synthesis
of biologically active heterocyclic compounds [19,20], we
introduced herein the new coumarin derivatives bearing
substituted 3,4-dihydro-2H-benzothiazines as analgesic
agents. The antinociceptive properties of target compounds
were determined by formalin-induced paw licking test andLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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formalin-induced paw licking method is used to investigate
both peripheral and central mechanisms whereas the acetic
acid test is believed to demonstrate the involvement of
peripheral mechanisms in the control of pain [21,22].Materials and methods
Chemistry
The target compounds 3-(3-methyl-3,4-dihydro-2H-benzo
[b][1,4]thiazin-3-yl)-2H-chromen-2-ones 2a-r (Additional
file 1: Table S1) were synthesized according to the pathway
outlined in Scheme 1 [23]. All reagents and chemicals were
commercially available and used as received. Alumina-
supported potassium fluoride (KF/Al2O3) was prepared by
literature method [24]. The dihydrobenzothiazole deriva-
tives 1 were prepared as reported method by us [19,20].
The synthesis of compounds 2a-d, 2f-i and 2p-r was de-
scribed in our previous paper [23]. Column chromatog-
raphy was carried out on silica gel (70–230 mesh). TLC
was conducted on silica gel 250 micron, F254 plates. Melt-
ing points were measured on a Kofler hot stage apparatus
and are uncorrected. The IR spectra were taken using
Nicolet FT-IR Magna 550 spectrographs (KBr disks). 1H
NMR spectra were recorded on a Bruker 400 or 500 MHz
NMR instruments. The chemical shifts (δ) and coupling
constants (J) are expressed in parts per million and Hertz,
respectively. Mass spectra of the products were obtained
with an HP (Agilent technologies) 5937 Mass Selective
Detector. Elemental analyses were carried out by a
CHN-Rapid Heraeus elemental analyzer. The results of












Scheme 1 Synthesis of coumarin based dihydrobenzothiazines 2a-u.
(0.7 g), quinine hydrochloride (10 mol%), EtOH (3 mL), r.t. (b) phenacyl halid
(3 mL), r.t.General procedure for the synthesis of compounds 2
A suspension of dihydrobenzothiazole derivatives 1
(1.0 mmol), KF/Al2O3 (0.7 g), and quinine hydrochloride
(10 mol%) in ethanol (3.0 mL) was stirred at room
temperature for 5 min. Then, appropriate phenacyl halide
(1.2 mmol) was added to the mixture and stirring was
continued. After completion of the reaction (3–5 h), the
solvent was removed under reduced pressure. The residue
was mixed with ethyl acetate (5 mL) and the catalyst was
filtered and washed with ethyl acetate (3 × 5 mL). After
evaporation of the solvent at reduced pressure, the crude
product was purified by column chromatography (n-
hexane/ethyl acetate, 9:1) and crystallized from ethanol
for further purification.3-(2-(3,4-Dichlorobenzoyl)-3-methyl-3,4-dihydro-2H-benzo[b]
[1,4]thiazin-3-yl)-2H-chromen-2-one (2e)
Yellow solid (361 mg, 75%); syn-isomer; mp 91–93°C; IR
(KBr, cm-1) 3382 (NH), 1708 (C=O); 1H NMR (500 MHz,
CDCl3) δ
1H NMR (500 MHz, CDCl3) δ 1.94 (s, 3H, CH3
benzothiazine), 4.49 (s, 1H, NH), 5.77 (s, 1H, C-H ben-
zothiazine), 6.75 (dt, J = 7.2 and 1.2 Hz, 1H, H7 benzothia-
zine), 6.95 (m, 2H, H5,8 benzothiazine), 7.14 (dt, J = 7.2
and 1.2 Hz, 1H, H6 benzothiazine), 7.22 (t, J = 8.0 Hz, 1H,
H6 chromene), 7.28 (dd, J = 8.0 and 1.9 Hz, 1H, H5 ben-
zoyl), 7.33 (d, J = 8.0 Hz, 1H, H6 benzoyl), 7.40 (m, 2H,
H5,8 chromene), 7.43 (d, J = 1.9, 1H, H3 benzoyl), 7.49 (dt,
J = 8.0 and 1.2 Hz, 1H, H7 chromene), 7.77 (s, 1H, H4
chromene); 13C NMR (125 MHz, CDCl3) δ 24.3, 42.9,
58.0, 110.9, 116.1, 117.1, 119.1, 119.3, 124.3, 127.0, 127.1,
128.4, 128.7, 130.1, 130.8, 131.2, 131.4, 132.0, 136.9,
















Reagents and conditions: (a) phenacyl halide (1.2 mmol), KF/Al2O3
e (2.5 mmol), KF/Al2O3 (1.5 g), quinine hydrochloride (10 mol%), EtOH
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62.41; H, 3.67; N, 3.15.
3-(2-(4-Fluorobenzoyl)-3-methyl-3,4-dihydro-2H-benzo[b]
[1,4]thiazin-3-yl)-2H-chromen-2-one (2j)
Yellow solid (336 mg, 78%); syn-isomer; mp 161–163°C; IR
(KBr, cm-1) 3413 (NH), 1708 (C=O); 1H NMR (500 MHz,
CDCl3) δ 1.76 (s, 3H, CH3 benzothiazine), 4.50 (s, 1H,
NH), 5.97 (s, 1H, C-H benzothiazine), 6.73 (t, J = 7.4 Hz,
1H, H7 benzothiazine), 6.93 (m, 2H, H5,6 benzothiazine),
7.14 (m, 3H, H8 benzothiazine and H3,5 benzoyl), 7.28 (t,
J = 7.4 Hz, 1H, H6 chromene), 7.35 (d, J = 7.4 Hz, 1H, H8
chromene), 7.40 (d, J = 7.4 Hz, 1H, H5 chromene), 7.50 (t,
J = 7.4 Hz, 1H, H7 chromene), 7.79 (s, 1H, H4 chromene),
8.05 (m, 2H, H2,6 benzoyl);
13C NMR (125 MHz, CDCl3) δ
24.6, 37.5, 57.6, 111.9, 115.7, 115.9, 116.1, 119.1, 119.4,
124.4, 126.7, 128.4, 128.5, 131.2, 131.3, 131.5, 133.2, 139.5,
141.1, 153.3, 161.3, 164.7, 166.7, 191.3; Anal. calcd for
C25H18FNO3S: C, 69.59; H, 4.20; N, 3.25. Found: C, 69.42;
H, 4.03; N, 3.47.
3-(3-Methyl-2-(thiophene-2-carbonyl)-3,4-dihydro-2H-benzo
[b][1,4]thiazin-3-yl)-2H-chromen-2-one (2k)
Yellow solid (356 mg, 85%); as mixture of diastereomers
(anti/syn: 15/85); IR (KBr, cm-1) 3389 (NH), 1707 (C=O);
1H NMR (500 MHz, CDCl3) δ 1.77syn (s, CH3 benzo-
thiazine), 1.87anti (s, CH3 benzothiazine), 4.48syn (s, NH),
4.53anti (s, NH), 5.50anti (s, C-H benzothiazine), 5.87syn
(s, C-H benzothiazine), 6.77syn (t, J = 8.0, H7 benzothiazine),
6.81anti (t, J = 8.0, H7 benzothiazine), 6.92anti (d, J = 8.0 Hz,
H5 benzothiazine), 6.95syn (d, J = 8.0 Hz, H5 benzothiazine),
7.07-7.10anti (m, H6,8 benzothiazine), 7.10-7.13syn (m, H6,8
benzothiazine), 7.20syn (t, J = 7.6 Hz, H7 chromene), 7.25syn
(t, J = 7.6 Hz, H6 chromene), 7.25-7.29anti (m, H4 thiophene
and H7 chromene), 7.38syn (d, J = 7.6 Hz, H5 chromene),
7.42syn (d, J = 7.6 Hz, H8 chromene), 7.48-7.54 (m, H5,7,8
chromene (anti) and H4 thiophene (syn)), 7.56anti (d, J = 4.0,
H3 thiophene), 7.74syn (d, J = 4.0, H3 thiophene), 7.79anti (d,
J = 4.0, H5 thiophene), 7.80syn (s, H4 chromene), 7.97syn (d,
J = 4.0, H5 thiophene), 8.15anti (s, H4 chromene);
13C NMR
(syn-isomer, 125 MHz, CDCl3) δ 27.5, 45.3, 54.2, 116.1,
117.0, 118.6, 119.0, 120.1, 124.5, 126.2, 127.1, 128.2, 128.4,
131.4, 131.7, 132.2, 134.4, 140.2, 140.9, 143.5, 153.1, 160.1,
186.8; Anal. calcd for C23H17NO3S2: C, 65.85; H, 4.08; N,
3.34. Found: C, 65.92; H, 3.91; N, 3.29.
3-(2-(5-Bromothiophene-2-carbonyl)-3-methyl-3,4-dihydro-
2H-benzo[b][1,4]thiazin-3-yl)-2H-chromen-2-one (2l)
Yellow solid (378 mg, 77%); as mixture of diastereomers
(anti/syn: 26/74); IR (KBr, cm-1) 3390 (NH), 1712 (C=O);
1H NMR (500 MHz, CDCl3) δ 1.75syn (s, CH3 benzo-
thiazine), 1.87anti (s, CH3 benzothiazine), 4.45syn (s, NH),
4.55anti (s, NH), 5.48anti (s, C-H benzothiazine), 5.78syn
(s, C-H benzothiazine), 6.76syn (t, J = 8.0, H7 benzothiazine),6.81anti (t, J = 8.0, H7 benzothiazine), 6.92syn (d, J = 8.0 Hz,
H5 benzothiazine), 6.94anti (d, J = 8.0 Hz, H5 benzothiazine),
6.92anti (d, J = 8.0 Hz, H8 benzothiazine), 6.96syn (d, J =
8.0 Hz, H8 benzothiazine), 7.09anti (t, J = 8.0 Hz, H6 ben-
zothiazine), 7.12syn (t, J = 8.0 Hz, H6 benzothiazine), 7.16syn
(d, J = 4.0 Hz, H4 thiophene), 7.23anti (d, J = 4.0 Hz, H4 thio-
phene), 7.24syn (t, J = 7.5, H6 chromene), 7.27-7.29anti (m,
H6,8 chromene), 7.36syn (d, J = 7.5 Hz, H8 chromene),
7.40syn (d, J = 7.5 Hz, H5 chromene), 7.50 syn (t, J = 7.5 Hz,
H7 chromene), 7.51-7.53anti (m, H5,7 chromene), 7.56anti (d,
J = 4.0 Hz, H3 thiophene), 7.69syn (d, J = 4.0 Hz, H3 thio-
phene), 7.77syn (s, H4 chromene), 8.15anti (s, H4 chromene);
13C NMR (syn-isomer, 125 MHz, CDCl3) δ 24.8, 38.7, 57.4,
112.3, 116.1, 116.9, 119.1, 119.5, 123.6, 124.4, 126.6, 128.1,
128.4, 130.8, 131.5, 131.6, 132.4, 139.2, 141.0, 145.9, 153.3,
161.2, 185.6; MS, m/z (%) 499 ([M+ 2]+, 40%), 497 (M+, 37),
375 (47), 373 (44), 308 (100), 294 (51), 280 (84); Anal. calcd
for C23H16BrNO3S2: C, 55.43; H, 3.24; N, 2.81 Found: C,
55.22; H, 3.47; N, 2.73.
3-(3-Methyl-2-(thiophene-3-carbonyl)-3,4-dihydro-2H-benzo
[b][1,4]thiazin-3-yl)-2H-chromen-2-one (2m)
Yellow solid (335 mg, 80%); as mixture of diastereomers
(anti/syn: 32/68); IR (KBr, cm-1) 3374 (NH), 1708 (C=O);
1H NMR (500 MHz, CDCl3) δ 1.77syn (s, CH3 benzo-
thiazine), 1.87anti (s, CH3 benzothiazine), 4.50anti (s, NH),
4.55syn (s, NH), 5.48anti (s, C-H benzothiazine), 5.81syn
(s, C-H benzothiazine), 6.74syn (t, J = 7.5, H7 benzothiazine),
6.80anti (t, J = 7.5, H7 benzothiazine), 6.93anti (d, J = 7.5 Hz,
H5 benzothiazine), 6.97syn (d, J = 7.5 Hz, H5 benzothiazine),
7.08anti (d, J = 7.5 Hz, H8 benzothiazine), 7.12syn (t,
J = 7.5 Hz, H6 benzothiazine), 7.13syn (t, J = 7.2 Hz, H6
chromene), 7.24-7.25syn (m, H8 benzothiazine and H8
chromene), 7.26-7.29anti (m, H6 benzothiazine and H6,8
chromene), 7.35-7.37syn (m, H4 thiophene and H5,7 chro-
mene), 7.37-7.40anti (m, H6 chromene and H4 thiophene),
7.50-7.53anti (m, H7 chromene and H5 thiophene), 7.58syn
(d, J = 5.0 Hz, H5 thiophene), 7.79anti (s, H2 thiophene),
8.04syn (s, H2 thiophene), 8.14anti (s, H4 chromene), 8.25syn
(s, H4 chromene);
13C NMR (syn-isomer, 125 MHz,
CDCl3) δ 27.8, 45.7, 54.4, 116.1, 116.8, 119.1, 119.9, 124.6,
126.3, 126.5, 127.3, 128.2, 128.4, 130.6, 131.5, 131.7, 132.6,
140.0, 140.2, 141.2, 153.1, 160.2, 187.7; MS, m/z (%) 419
(M+, 68%), 404 (12), 386 (12), 308 (97), 295 (100), 280
(64), 111 (63); Anal. calcd for C23H17NO3S2: C, 65.85; H,
4.08; N, 3.34. Found: C, 65.98; H, 3.82; N, 3.60.
8-Methoxy-3-(3-methyl-2-(4-methylbenzoyl)-3,4-dihydro-2H-
benzo[b][1,4]thiazin-3-yl)-2H-chromen-2-one (2n)
Yellow solid (343 mg, 75%); syn-isomer; mp 145–147°C; IR
(KBr, cm-1) 3360 (NH), 1700 (C=O); 1H NMR (500 MHz,
CDCl3) δ 1.77 (s, 3H, CH3 benzothiazine), 2.43 (s, 3H,
CH3 benzoyl), 3.90 (s, 3H, O-CH3 chromene), 4.52 (s, 1H,
NH), 6.00 (s, 1H, C-H benzothiazine), 6.78 (dt, J = 7.5 and
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1H, H7 chromene), 7.02-7.11 (m, 4H, H5,6,8 benzothiazine
and H6 chromene), 7.18 (m, 3H, H5 chromene and H3,5
benzoyl), 7.74 (d, J = 8.3 Hz, 2H, H2,6 benzoyl), 8.13 (s, 1H,
H4 chromene);
13C NMR (125 MHz, CDCl3) δ 21.6, 27.9,
43.6, 54.6, 56.1, 113.3, 114.8, 118.9, 119.4, 119.7, 119.9,
124.3, 126.3, 127.4, 128.5, 129.3, 131.1, 133.7, 140.0, 140.2,
142.8, 143.8, 146.7, 159.5, 192.9 cm-1; Anal. calcd for
C27H23NO4S: C, 70.88; H, 5.07; N, 3.06. Found: C, 70.64;
H, 5.23; N, 3.22.
3-(2-(4-Fluorobenzoyl)-3-methyl-3,4-dihydro-2H-benzo[b]
[1,4]thiazin-3-yl)-8-methoxy-2H-chromen-2-one (2o)
Yellow solid (323 mg, 70%); syn-isomer; mp 236–238°C; IR
(KBr, cm-1) 3398 (NH), 1690 (C=O); 1H NMR (500 MHz,
CDCl3) δ 1.78 (s, 3H, CH3 benzothiazine), 3.98 (s, 3H,
O-CH3 chromene), 4.51 (s, 1H, NH), 5.98 (s, 1H, C-H ben-
zothiazine), 6.74 (t, J = 7.4 Hz, 1H, H7 benzothiazine), 6.93
(m, 2H, H5,6 benzothiazine), 6.98 (d, J = 8.0 Hz, 1H, H7
chromene), 7.05 (m, 2H, H5,6 chromene), 7.16 (m, 3H, H8
benzothiazine and H3,5 benzoyl), 7.77 (s, 1H, H4 chro-
mene), 8.05 (m, 2H, H2,6 benzoyl);
13C NMR (125 MHz,
CDCl3) δ 24.5, 37.4, 56.3, 57.6, 111.9, 113.3, 115.7, 115.9,
116.9, 119.3, 119.8, 124.2, 126.7, 128.4, 131.2, 131.3, 131.4,
133.1, 139.5, 141.2, 146.8, 160.7, 164.7, 166.7, 191.2; Anal.
calcd for C26H20FNO4S: C, 67.67; H, 4.37; N, 3.04. Found:




Yellow solid (507 mg, 72%); as mixture of diasteromers
(anti/syn: 18/82); IR (KBr, cm-1) 3382 (NH), 1697 (C=O);
1H NMR (500 MHz, CDCl3) δ 1.74syn (s, CH3 benzothia-
zine), 1.85anti (s, CH3 benzothiazine), 4.48anti (s, NH),
4.51syn (s, NH), 5.29anti (s, O-CH2), 5.31syn (s, O-CH2),
5.60anti (s, C-H benzothiazine), 5.91syn (s, C-H benzothia-
zine), 6.71anti (t, J = 7.5, H7 benzothiazine), 6.73syn (t, J = 7.5,
H7 benzothiazine), 6.80anti (s, H8 chromene), 6.82syn (s, H8
chromene), 6.87syn (d, J = 8.5 Hz, H6 chromene), 6.90anti (d,
J = 8.5 Hz, H6 chromene), 6.93syn (d, J = 8.0 Hz, H3,5
phenyl-2-oxoethoxy), 7.05anti (d, J = 8.0 Hz, H3,5 phenyl-
2-oxoethoxy), 7.07anti (t, J = 7.5 Hz, H6 benzothiazine),
7.12syn (t, J = 7.5 Hz, H6 benzothiazine), 7.33syn (d, J = 8.5,
H5 chromene), 7.44anti (d, J = 8.5, H5 chromene), 7.52anti
(d, J = 8.5, H3,5 benzoyl), 7.63syn (d, J = 8.0 Hz, H3,5 ben-
zoyl), 7.64-7.67anti (m, H5,8 benzothiazine), 7.68syn (m, H5,8
benzothiazine), 7.72syn (s, H4 chromene), 7.82-7.85anti (m,
H2,6 benzoyl and H2,6 phenyl-2-oxoethoxy), 7.85-7.89syn
(m, H2,6 benzoyl and H2,6 phenyl-2-oxoethoxy), 8.06anti (s,
H4 chromene);
13C NMR (syn-isomer, 125 MHz, CDCl3) δ
24.5, 37.6, 57.4, 70.6, 101.1, 111.8, 112.9, 116.9, 118.7,
119.3, 126.7, 128.3, 128.4, 129.5, 129.6, 129.9, 130.0, 131.9,
132.0, 132.3, 132.8, 135.5, 139.6, 140.9, 154.7, 160.6, 161.3,191.6, 192.4; Anal. calcd for C33H23Br2NO5S: C, 56.19; H,




Yellow solid (397 mg, 70%); as mixture of diastereomers
(anti/syn: 30/70); IR (KBr, cm-1) 3397 (NH), 1702 (C=O);
1H NMR (500 MHz, CDCl3) δ 1.74syn (s, CH3 benzo-
thiazine), 1.85anti (s, CH3 benzothiazine), 2.36anti (s, CH3
phenyl-2-oxoethoxy), 2.42syn (s, CH3 phenyl-2-oxoethoxy),
2.44anti (s, CH3 benzoyl), 2.45syn (s, CH3 benzoyl), 4.50syn
(s, NH), 4.61anti (s, NH), 5.31anti (s, O-CH2), 5.35syn (s, O-
CH2), 5.61anti (s, C-H benzothiazine), 5.96syn (s, C-H ben-
zothiazine), 6.69anti (d, J = 2.1 Hz, H8 chromene), 6.72syn (t,
J = 7.3 Hz, H7 benzothiazine), 6.75anti (t, J = 7.3 Hz, H7 ben-
zothiazine), 6.81syn (d, J = 2.1 Hz, H8 chromene), 6.87syn
(dd, J = 8.0 and 2.1 Hz, H6 chromene), 6.90-6.93syn/anti (m,
H5,8 benzothiazine), 7.05anti (t, J = 7.3 Hz, H6 benzo-
thiazine), 7.11syn (t, J = 7.3 Hz, H6 benzothiazine), 7.17anti
(d, J = 8.0 Hz, H3,5 phenyl-2-oxoethoxy), 7.28-7.33 (m, H5
chromene (syn/anti), H3,5 benzoyl (syn/anti) and H3,5
phenyl-2-oxoethoxy (syn)), 7.34anti (d, J = 8.0 Hz, H2,6
phenyl-2-oxoethoxy), 7.73syn (s, H4 chromene), 7.79anti (d,
J = 8.0 Hz, H2,6 benzoyl), 7.87syn (d, J = 8.0 Hz, H2,6 phenyl-
2-oxoethoxy), 7.94syn (d, J = 8.0 Hz, H2,6 benzoyl), 8.06anti
(s, H4 chromene);
13C NMR (syn-isomer, 125 MHz,
CDCl3) δ 24.0, 27.7, 32.6, 43.3, 56.0, 80.2, 110.4, 110.6,
113.6, 116.1, 118.7, 118.9, 119.9, 122.4, 124.5, 126.2,
127.2, 128.4, 129.2, 131.6, 140.1, 154.2, 161.2, 161.4,
192.1, 192.6; MS, m/z (%) 575 (M+, 8%), 557 (64), 542
(43), 410 (35), 264 (44), 239 (29), 119 (100); Anal. calcd
for C35H29NO5S: C, 73.02 ; H, 5.08; N, 2.43. Found: C,




Yellow solid (576 mg, 82%); as mixture of diastereomers
(anti/syn: 28/72); IR (KBr, cm-1) 3394 (NH), 1688 (C=O),
1320 (SO2), 1153 (SO2);
1H NMR (500 MHz, CDCl3) δ
1.78syn (s, CH3 benzothiazine), 1.89anti (s, CH3 benzothia-
zine), 3.02anti (s, SO2-CH3 phenyl-2-oxoethoxy), 3.04anti
(s, SO2-CH3 benzoyl), 3.09syn (s, SO2-CH3 phenyl-2-
oxoethoxy), 3.12syn (s, SO2-CH3 benzoyl), 4.50anti (s, NH),
4.69syn (s, NH), 5.37syn (s, O-CH2), 5.41anti(s, O-CH2),
5.61anti (s, C-H benzothiazine), 5.95syn (s, C-H benzothia-
zine), 6.69anti (s, H8 chromene), 6.74syn (t, J = 7.5, H7 ben-
zothiazine), 6.80anti (t, J = 7.5, H7 benzothiazine), 6.83syn (s,
H8 chromene), 6.88-6.95syn (m, H6 chromene and H5,8
benzothiazine), 7.08anti (d, J = 8.0, H6 chromene), 7.11anti
(t, J = 7.5, H6 benzothiazine), 7.13syn (t, J = 7.5 Hz, H6
benzothiazine), 7.36syn (d, J = 8.0, H5 chromene), 7.50anti
(d, J = 8.0, H5 chromene), 7.59anti (d, J = 7.5 Hz, H8
Alipour et al. DARU Journal of Pharmaceutical Sciences 2014, 22:9 Page 5 of 8
http://www.darujps.com/content/22/1/9benzothiazine), 7.74syn (s, H4 chromene), 7.82anti (d, J =
7.5 Hz, H5 benzothiazine), 7.94anti (s, H4 chromene), 8.04-
8.19syn/anti (m, H2,3,5,6 phenyl-2-oxoethoxy and H2,3,5,6
benzoyl); 13C NMR (syn-isomer, 125 MHz, CDCl3) δ 24.5,
44.2, 44.3, 57.5, 65.5, 70.9, 101.0, 110.9, 113.0, 116.9, 119.4,
126.9, 127.4, 127.9, 128.1, 128.5, 129.1, 129.3, 129.8, 138.0,
139.6, 140.8, 141.0, 143.9, 145.1, 154.7, 160.4, 161.2, 190.6,
192.6; Anal. calcd for C35H29NO9S3: C, 59.73 ; H, 4.15; N,
1.99. Found: C, 59.59; H, 4.31; N, 2.30.
Pharmacology
Animals
Male NMRI mice weighing 20–30 g were used for study-
ing in vivo antinociceptive activities of target compounds.
Animals were maintained under standard conditions (24 ±
2°C, 60-70% humidity) and allowed food and water ad
libitum. They were housed in appropriate cages with 12 h
light/dark cycle. Before each experiment animals randomlyTable 1 Antinociception activity of target compounds 2a-u an
test in mice
Compounds Phase 1
Licking timea Inhibitionb (%) Relative a
2a 58 ± 3.46 48.10** 0.54
2b 51.33 ± 2.96 54.06*** 0.61
2c 68.33 ± 4.05 38.85** 0.44
2d 55 ± 2.74 50.78*** 0.57
2e 44 ± 2.89 60.63*** 0.68
2f 60.33 ± 3.76 46.01** 0.52
2g 56.66 ± 8.74 49.29** 0.55
2h 70.25 ± 2.95 37.14** 0.42
2i 51.33 ± 2.40 54.06*** 0.61
2j 46.25 ± 2.56 58.61*** 0.66
2k 51.66 ± 2.18 53.77*** 0.60
2l 70 ± 11.13 37.36** 0.42
2m 63.33 ± 8.21 43.33** 0.49
2n 69 ± 9.16 38.26** 0.43
2o 53.8 ± 3.21 51.85** 0.58
2p 53.9 ± 3.18 51.76** 0.58
2q 61.33 ± 5.78 45.12** 0.51
2r 94.4 ± 4.89 25.86** 0.29
2s 50 ± 3.22 33.33** 0.37
2t 46 ± 2.4 38.86** 0.43
2u 34.8 ± 2.65 53.6*** 0.61
Control 111.75 ± 6.94 - -
Mefenamic acid 12.33 ± 3.93 88.96*** 1
aData are expressed as mean ± S.E.M (number of animals in each group, n = 6).
bThe percentage inhibition was determined by using the following formula: Inhibiti
significance in comparison with control groups (*P <0.05, **P <0.01 and ***P <0.001
cActivity relative to mefenamic acid was determined by using the following formulaselected and allocated into groups. The whole protocol
was approved by the Ethics Committee of the Faculty of
Pharmacy at Tehran University of Medical Sciences.Formalin-induced pain test
All target compounds 2a-u were subjected for testing their
analgesic activity using formalin paw test [25]. The com-
pounds or standard drug mefenamic acid were adminis-
tered i.p. (30 mg/kg, 0.2 mL/20 g body weight) as a
suspension in saline and tween 80 (4% w/v). Each group of
mice (n = 6 animals per group) were pretreated by test
compounds, mefenamic acid or vehicle, 30 minutes before
injection of formalin (20 μL, 0.5%, s.c.) into the planar sur-
face of the right hind paw. The amount of time that the
animal spent licking injected paw was measured during
the first 10 minutes (phase 1, neurogenic) and 10–30 mi-
nutes (phase 2, inflammatory) after formalin injection.d mefenamic acid (30 mg/kg, i.p.) assessed by formalin
Phase 2
ctivityc Licking time Inhibition (%) Relative activity
37.33 ± 3.93 44.28** 0.52
50.33 ± 4.91 24.88 0.29
38 ± 1.73 43.28** 0.51
57.33 ± 6.35 14.43 0.17
54 ± 4.93 19.40 0.23
38.33 ± 4.63 42.79** 0.50
55.66 ± 3.92 16.92 0.20
38 ± 1 43.28** 0.51
37 ± 1.15 44.78** 0.53
50.33 ± 0.33 24.88 0.29
51.66 ± 5.54 22.89 0.27
37 ± 4.35 44.78** 0.53
18.33 ± 0.33 72.64*** 0.85
40.66 ± 1.20 39.30** 0.46
65 ± 6.41 2.98 0.03
64.8 ± 4.19 3.28 0.04
49.5 ± 2.02 26.12 0.31
11 ± 1.7 93.64*** 1.1
5.2 ± 2.78 96.99*** 1.14
3 ± 1.04 98.26*** 1.15
14.8 ± 1.92 91.44*** 1.07
67 ± 3.14 - -
10 ± 2.52 85.07*** 1
on % = 100 × (control – experiment)/control. The asterisks denote the levels of
).
: Relative Activity = Inhibition % of compound/Inhibition % of mefenamic acid.
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The analgesic activity was also determined in vivo by the
abdominal constriction test induced by acetic acid (0.6%;
0.1 mL/10 g) in mice [21]. An acetic acid solution was ad-
ministered i.p. 30 minutes after administration of com-
pounds or mefenamic acid. After the treatment, pairs of
mice were placed in separate boxes and the numbers of
constrictions of the abdominal muscles, together with
stretching, were counted cumulatively over a period of
60 minutes. Antinociceptive activity was expressed as the
percentage of inhibition of constrictions when compared
with the vehicle control group.
Statistical analysis
The nociception data are expressed as means ± SEM.
Variance analysis (ANOVA) followed by Bonferroni’s test
was used to compare means. P-values less than 0.05
were considered to be statistically significant.
Results and discussion
Chemistry
The dihydrobenzothiazole derivatives 1 were quantita-
tively obtained by reaction of 3-acetylcoumarins with 2-
aminothiophenol derivatives in the presence of acetic acid
under reflux condition or microwave irradiation [19,20].
The intramolecular Mannich-type reaction of compounds
1 with different phenacyl halides in the present of KF/
Al2O3 and catalyzing by quinine hydrochloride in ethanol
afforded 3,4-dihydro-2H-benzothiazine derivatives 2a-r
via a ring expansion. When 7-hydroxy-3-(benzothiazol-2-Table 2 Antinociception activity of selected compounds in co
by acetic acid-induced writhing test in mice
Compound Nociception (Mean ± SEM)
2b 0.6 ± 0.24***
2c 38 ± 4.04***
2d 9.6 ± 2.54***
2g 3.5 ± 1.09***
2h 3 ± 1.84***
2i 4.6 ± 2***
2k 20 ± 2.48***
2o 6 ± 3.2***
2r 29 ± 2.12***
2s 14 ± 2.28***
2t 30 ± 7.6***
2u 2 ± 1.3***
Controlc 75 ± 3.2
Mefnamic acid 23 ± 1.3***
aThe percentage inhibition was determined by using the following formula: Inhibiti
bActivity relative to mefenamic acid was determined by using the following formula
cTween 80 in saline (4% w/v).
***P <0.001 vs. control.yl) coumarin derivative 1e was treated with 2.5 equivalents
of phenacyl halides, without protection of hydroxyl group,
O-phenacyl derivatives 2s-u was obtained in excellent
yields (Scheme 1). The physicochemical and spectral data




All target compounds 2a-u were tested using formalin-
induced pain test in mice [25]. The obtained results were
reported as mean ± SEM of licking time and as percent
of inhibition in Table 1. In general, the results showed
that most of compounds were significantly able to re-
duce the licking time with percent of inhibition in the
range of 25% to 60% at the first phase. The standard
drug mefenamic acid showed 89% reduction of the lick-
ing time during the first phase. Amongst the tested com-
pounds, 2a, 2c, 2f, 2h, 2i, 2l-n and 2r-u significantly
reduced the formalin induced licking time in the range
of 39-98% as compared to mefenamic acid with 85% of
inhibition during the second phase. Compounds 2m and
2r-u showed more effective antinociceptive activity in
the second phase rather than first phase, indicating their
ability to inhibit nociception associated with inflamma-
tory response. Indeed, 7-hydroxy- and 7-phenacyloxy-
coumarin derivatives (2r and 2s-u, respectively) were
more effective than mefenamic acid. Compounds 2s and
2t were the most effective compounds at the dose of
30 mg/kg.mparison with mefenamic acid (30 mg/kg, i.p.) assessed














on% = 100 × (control – experiment)/control.
: Relative Activity = Inhibition % of compound/Inhibition % of mefenamic acid.
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The analgesic activity of compounds 2b-d, 2g-i, 2k, 2o
and 2r-s was also evaluated in vivo by using abdominal
constriction test induced by acetic acid in mice [21]. The
abdominal constriction response induced by acetic acid
is sensitive procedure to establish efficacy of peripherally
acting analgesics. The analgesic activity was expressed as
the percentage of inhibition of constrictions when com-
pared with the control group. The results are summa-
rized in Table 2.
Significant protection against writhing was observed in
animals treated with all test compounds where the mean
numbers of writhes after 1 h were less than 38 compared
to 75 in the control group. The percent of inhibition was
in the range of 49-99%. All tested compounds were more
effective than standard drug mefenamic acid with the ex-
ception of 2c, 2r and 2t. Compounds 2b and 2u with
percent of inhibition ≥98% were the most effective com-
pounds in acetic acid-induced writhing test. Moreover,
compounds 2g-i and 2o exhibited high protection against
writhing (percent of inhibition > 90%).
Structure–activity relationships
From the structure–activity relationships of unsubstituted
coumarin series (compound 2a-m) based on the late
stage of formalin-induced test, it was inferred that 3-
thienylcarbonyl group is more favorable for activity. By
comparing the activity of 7-substituted coumarin com-
pounds 2r-u with those of other compounds it is appeared
that the 7-hydroxy or 7-phenacyloxy groups dramatically
increase the effectiveness of compounds and their ability
to inhibit nociception associated with inflammatory re-
sponse. On contrary, compounds 2r-u showed low level of
inhibition at early phase of formalin test.
By comparing the percent of inhibition of 4-(methylsul-
fonyl)benzoyl derivatives 2d, 2r and 2u, it is revealed that
the introduction of hydroxyl group on 7-position of cou-
marin ring diminished the antinociception activity, while
the introduction of 4-(methylsulfonyl)phenacyloxy- group
increased the activity as resulted from writhing test. In the
7-phenacyloxy-coumarin derivatives 2s-u, methylsulfonyl
substituent was more favorable than bromo and methyl
groups. The observed results of unsubstituted coumarin
derivatives in Table 2 demonstrate that electron donating
or bulky groups (for example, methoxy or phenyl, respect-
ively) can increase antinociceptive activity in writhing test.
Conclusion
In summary, a series of 3-(3-methyl-3,4-dihydro-2H-
benzo[b][1,4]thiazin-3-yl)-2H-chromen-2-one derivatives
2a-u bearing different aroyl group on the 2-position of
benzothiazine ring were described as potential analgesic
agents. The antinociceptive properties of target com-
pounds were determined by formalin-induced test andacetic acid-induced writhing test in mice. The effect of
substituent on aroyl moiety was explored by introduction
of various electron withdrawing, electron donating or
bulky groups. Surprisingly, compound 2u bearing 2-[4-
(methylsulfonyl)benzoyl]- moiety on benzothiazine ring
and 4-(methylsulfonyl)phenacyloxy- group on the 7 pos-
ition of coumarin nucleus showed better profile of antino-
ceciption in both models. It was more effective than
mefenamic acid during the late phase of formalin-induced
test as well as in the acetic acid-induced writhing test.
However, unsubstituted coumarin derivative 2b containing
4-methylbenzoyl moiety on benzothiazine ring, fully pro-
tected animals against writhing and was moderately able
to inhibit the both phases of the formalin test. Considering
the significant antinoceciptive action of phenacyloxy-
coumarin derivatives, compound 2u prototype might be
further used as model to obtain new more potent anal-
gesic drugs.
Additional file
Additional file 1: Table S1. Chemical structure of coumarin
compounds 2a-u.
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